This Phase II trial, sponsored by Ruijin Hospital, aims to evaluate the efficacy and safety of a novel treatment regimen combining decitabine and cytarabine with unrelated cord blood transplantation in elderly patients with AML. Given the aging population and the high unmet medical need in this demographic, successful outcomes could position this therapy favorably in a competitive market. The trial's focus on a vulnerable patient population (aged 60-75) highlights potential for market differentiation. However, the absence of FDA regulation may limit immediate commercial viability in certain markets. The results could attract interest from larger biopharmaceutical companies for potential partnerships or acquisitions, especially if the regimen demonstrates superior outcomes compared to traditional therapies.